United Kingdom Type 1 Diabetes Treatment Market Insight
United Kingdom Type 1 Diabetes Treatment Market is growing at an 8.36% CAGR, by increasing diabetes prevalence, advanced insulin therapies
United Kingdom Type 1 Diabetes Treatment Market Insights Forecasts to 2035
- The United Kingdom Type 1 Diabetes Treatment Market Size Was Estimated at USD 18.01 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 8.36% from 2025 to 2035
- The United Kingdom Type 1 Diabetes Treatment Market Size is Expected to Reach USD 40.2 Million by 2035
Notable Insights for United Kingdom Type 1 Diabetes Treatment Market
- By treatment type, insulin therapy dominated, accounting for approximately 75% share in 2024, driven by lifelong insulin dependence among Type 1 diabetes patients.
- By device type, continuous glucose monitoring systems held approximately 60% share, supported by growing adoption of real-time glucose monitoring technologies.
- Approximately 1.0% of the UK population is living with Type 1 diabetes, with increasing incidence observed among children and young adults.
- Around 85% of diagnosed patients use intensive insulin management approaches, while a smaller proportion adopt insulin pumps or combination digital diabetes care solutions.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Type 1 Diabetes Treatment Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Type 1 Diabetes Treatment Market
- Novo Nordisk
- Eli Lilly and Company
- Sanofi
- Medtronic
- Dexcom
- Abbott Laboratories
- Roche
- Insulet Corporation
- Others
Recent Developments:
- In March 2026: UK-funded Type 1 Diabetes Grand Challenge researchers reported encouraging progress in beta cell replacement therapies, including stem-cell islets and immune-protection strategies aiming to restore natural insulin production.
- In January 2026: Civica introduced low-cost long-acting insulin glargine-yfgn, expanding affordable insulin access and supporting global diabetes treatment affordability trends impacting the United Kingdom Type 1 Diabetes Treatment Market.
Market Segmentation:
United Kingdom Type 1 Diabetes Treatment Market, By Treatment Type
- Insulin Therapy
- Insulin Pumps
- Continuous Glucose Monitoring Systems
- Combination Therapy
- Others
United Kingdom Type 1 Diabetes Treatment Market, By Route of Administration
- Subcutaneous Infusion
- Injectable
United Kingdom Type 1 Diabetes Treatment Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Specialty Diabetes Centers
United Kingdom Type 1 Diabetes Treatment Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Type 1 Diabetes Treatment Market is expected to grow steadily due to improved screening programs, migration-linked prevalence, and long-term treatment requirements. Experts highlight that nucleos(t)ide analogue therapies will continue to dominate, supported by NHS treatment guidelines and increasing focus on liver disease elimination strategies. Advancements in antiviral drug development and functional cure research are expected to shape future market growth through 2035.